

FMOLHS Drug Shortage Memo

To: All Providers From: Pharmacy Department Date: 05/02/2023 Drug Affected: Methylpredisolone Injection

Dear Providers,

Currently, there is a shortage of **methylprednisolone injection** due to manufacturing delays and overutilization nationwide. At OLOLRMC, a limited supply is currently available and we do not have a date where supply chain and manufacturing will allow for acquisition of more product. As a result, we are attempting to restrict utilization where evidence-based medicine confirms the maximal potential benefit to the patients.

Methylprednisolone is an intermediate-acting glucocorticoid commonly used for its antiinflammatory/immunosuppressive properties, acute respiratory distress syndrome (ARDS), COVID-19, and COPD and asthma exacerbations. To conserve supply, the following recommendations during the period of shortage are:

- Consider usage of full vial sizes to minimize waste if dosing allows (available sizes: 40mg, 80mg, 125mg)
- Utilize dexamethasone for ARDS or COVID-19
- Add stop dates for glucocorticoid therapy when duration of therapy is defined in the literature (ex: REDUCE Trial³ dosing for COPD exacerbation; 5 day-course of therapy non-inferior to 14 day-course)
- Consider transitioning patients to oral prednisone
- Utilize alternative glucocorticoids when able (refer to table below for conversion and potency information)

Hydrocortisone 20mg	Prednisone 5mg	Methylprednisolone 4mg	Dexamethasone 0.75mg
40	10	8	1.5
50	12.5	10	2
60	15	12	2.25
65	17.5	13	2.5
80	20	16	3
100	25	20	4
200	50	40	8
250	65	50	10
300	75	60	12
400	100	80	15
500	125	100	20

Steroid Dose Conversion Chart^{1,2}



600	150	125	25
1200	300	250	50
2500		500	100
Hydrocortisone	Prednisone	Methylprednisolone	Dexamethasone
20mg	5mg	4mg	0.75mg
Short-Acting (half-life 8-12 hours)	Intermediate-Acting (half-life 18-36 hours)	Intermediate-Acting (half-life 18-36 hours)	Long-Acting (half-life 36-54 hours)
Convert 1:1 to PO hydrocortisone, may give in 2-3 divided doses	Prednisone (PO tablet)= Prednisolone (PO Liquid/ODT)	May convert to PO prednisone or prednisolone	Convert 1:1 to PO, recommended for daily administration
Glucocorticoid Potency: 1	Glucocorticoid Potency: 4-5	Glucocorticoid Potency: 5- 6	Glucocorticoid Potency: 18
Mineralocorticoid Potency:	Mineralocorticoid Potency:	Mineralocorticoid	Mineralocorticoid Potency:
1	0.8	Potency: 0.5	<0.01

For any questions/concerns, please contact:

Emily Johnston, PharmD, BCCCP Critical Care Clinical Pharmacy Specialist Manager, Clinical Pharmacy Services Our Lady of the Lake Regional Medical Center 5000 Hennessy Blvd| Baton Rouge, LA 70808 E: emily.johnston@fmolhs.org |P: 225-374-6779

References:

- Meikle AW, Tyler FH. Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. *Am J Med*. 1977;63(2):200-207. doi:10.1016/0002-9343(77)90233-9
- 2. Samuel S, Nguyen T, and Choi A. Pharmacologic Characteristic of Corticosteroids. J Neurocrit Care. 2017;10(2):53-59.
- Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs Conventional Glucocorticoid Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: The REDUCE Randomized Clinical Trial. JAMA. 2013;309(21):2223–2231. doi:10.1001/jama.2013.5023